June Edition: Parkinsons disease and the rate of ALS progression
b'In this podcast, Elizabeth Highton investigates the details of two studies selected for the June 2016 edition of JNNP.\\n\\nProfessor Steve Vucic, from the Department of Neurology at Westmead Hospital, Sydney, talks about the details of his study, which concludes that the rate of ALS progression appears to be a simple and sensitive clinical prognostic biomarker in the disease that could be potentially utilised in clinical practice and future therapeutic trials.\\nThe paper \\u201cRate of Disease Progression: A Prognostic Biomarker in ALS\\u201d, which was selected as Patient choice this month, can be read here: http://jnnp.bmj.com/content/87/6/628.full .\\n\\nDr Helen Ling, Senior Research Associate at UCL Institute of Neurology in London, explains the correlations of the diagnosis of Parkinson\\u2019s disease with the phenomenon of SWEDD.\\nRead the full study selected for Editor\\u2019s Choice, \\u201cParkinson\\u2019s disease without nigral degeneration: a pathological correlate of scans without evidence of dopaminergic deficit (SWEDD)?\\u201d here: http://jnnp.bmj.com/content/87/6/633.full.'